Silencing of ETS1 reverses adriamycin resistance in MCF-7/ADR cells via downregulation of MDR1

Cancer Cell International

Dong Xiao³  Guo-Qin Jiang²  Yong Zhou¹  Jinrong Wei² 

[1] Department of General Surgery, Yancheng City No. 1 People’s Hospital, Yancheng, Jiangsu 224005, China;Department of General Surgery, The Second Affiliated of Hospital of Soochow University, Suzhou, Jiangsu 215004, China;Department Urology, University of Pittsburgh Cancer Institute, University of Pittsburgh Medical College, University of Pittsburgh, Shadyside Medical Center, Suit G37, 5200 Center Avenue, Pittsburgh, PA 15232, USA

关键词: Breast cancer;    Drug efflux;    MDR1;    Multidrug resistance;    Adriamycin;    ETS1;   

Others  :  792249
DOI  :  10.1186/1475-2867-14-22

 received in 2013-08-05, accepted in 2014-01-29,  发布年份 2014

【 摘 要 】

Background

Clinical resistance to chemotherapeutic agents is one of the major hindrances in the treatment of human cancers. Erythroblastosis virus E26 oncogene homolog 1 (ETS1) is involved in the drug resistance of various cancer cells, and is overexpressed in drug-resistant human breast cancer cell lines. In this study, we investigated the effects of ETS1 on adriamycin resistance in MCF-7/ADR cells.

Methods

siRNAs against ETS1 or negative control siRNAs was transfected to MCF-7/ADR breast cancer cells. Reverse transcription-PCR and Western blotting were used to determine the mRNA and protein expression of ETS1 and MDR1. The cytotoxicity of adriamycin was assessed using the MTT assay. Drug efflux was investigated by flow cytometry using the Rhodamine 123 intracellular accumulation assay.

Results

ETS1 mRNA and protein was significantly overexpressed in MCF-7/ADR cells, compared to MCF-7 cells. ETS1 siRNA successfully silenced ETS1 mRNA and protein expression. Silencing of ETS1 also significantly reduced the mRNA and protein expression levels of MDR1 (multidrug resistance 1; also known as ABCB1, P-glycoprotein/P-gp), which is a major ATP-binding cassette (ABC) transporter linked to multi-drug resistance in cancer cells. Silencing of ETS1 significantly increased the sensitivity of MCF-7/ADR cells to adriamycin, compared to cells transfected with negative control siRNA. In addition, intracellular accumulation of Rhodamine 123 significantly increased in MCF-7/ADR cells transfected with ETS1 siRNA, indicating that silencing of ETS1 may reduce drug efflux.

Conclusions

This study demonstrates that drug resistance can be effectively reversed in adriamycin-resistant breast carcinoma cells through delivery of siRNAs targeting ETS1.

【 授权许可】

   
2014 Wei et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Kerbel RS: A cancer therapy resistant to resistance. Nature 1997, 390:335-336.
• [2]Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rew Cancer 2002, 2:48-58.
• [3]Young AM, Allen CE, Audus KL: Efflux transporters of the human placenta. Adv Drug Deliv Rev 2003, 55:125-132.
• [4]Ma Y, Wink M: Lobeline: a piperidine alkaloid from Lobe-lia can reverse P-gp dependent multi-drug resistance in tumor cells. Phytomedicine 2008, 15(9):754-758.
• [5]Bhardwaj A: Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor kappaβ-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007, 109:2293-2302.
• [6]Thomas H, Coley HM: Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003, 10:159-165.
• [7]Hao W, William NH, Yang JM: Small interfering RNA induced suppression of MDR1 (P-glycoprotein) restores sensitivity to Multi drug resistant cancer cells. Cancer Res 2003, 63(7):1515.
• [8]Wu Z, Li X, Zeng Y, Zhuang X, Shen H, Zhu H, Liu H, Xiao H: In vitro and in vivo inhibition of MRP gene expression and reversal of multi drug resistance by siRNA. Basic Clin Pharmacol Toxicol 2011, 108:177-184.
• [9]Ee PL, He X, Ross DD, Beck WT: Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol Cancer Ther 2004, 3:1577-1584.
• [10]Kars MD, Işeri OD, Gündüz U: Drug resistant breast cancer cells over-express Ets1 gene. Biomed Pharmacother 2010, 10:1016-1021.
• [11]Wilson LA, Yamamoto H, Singh G: Role of the transcription factor Ets-1 in cisplatin resistance. Mol Cancer Ther 2004, 3(7):823-832.
• [12]Khanna A, Mahalingam K, Chakrabarti D, Periyasamy G: Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells. Cell Mol Biol Lett 2011, 1(16):101-113.
• [13]Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998, 95(26):15665-15670.
• [14]Jiang GQ, Xiao M, Zeng Y, Nagabhushanam K, Majee M, Xiao D: Targeting beta-catenin signaling to induce apoptosis in human breast cancer cells by z-Guggulsterone and Gugulipid extract of Ayurvedic medicine plant Commiphora mukul. BMC Complement Altern Med 2013, 13:203. doi: 10.1186/1472-6882-13-203 BioMed Central Full Text
• [15]Ito H, Duxbury M, Benoit E, Clancy TE, Zinner MJ, Ashley SW, Whang EE: Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets1-dependent induction of matrix metalloproteinase-2. Cancer Res 2004, 64:7439-7446.
• [16]Lu Y, Pang TX, Wang JX, Xiong DS, Ma L, Li B, Li QH, Wakabayashi S: Down-regulation of P-glycoprotein expression by sustained intracellular acidification in K562/DOX cells. Biochem Biophy Res Comm 2008, 377:441-446.
• [17]Avendano C, Menendez J: Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem 2002, 9:159-193.
• [18]Coley HM: Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol Biol 2010, 596:341-358.
• [19]Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ: Gain of function mutations in p53. Nat Genet 1993, 4:42-46.
• [20]Fujimoto J, Aoki I, Toyoki H, Khatun S, Tamaya T: Clinical implications of expression of Ets1 related to angiogenesis in uterine cervical cancers. Ann Oncol 2002, 13:1598-1604.
• [21]Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, Beex LV, Sweep CG: Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 2002, 21:8506-8509.
• [22]Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, Ben-Baruch G, Bryne M, Nesland JM: Ets1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res 2001, 7:551-557.
• [23]Chaudhary PM, Roninson IB: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993, 85:632-639.
• [24]Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN: Over-expression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 2003, 1:420-427.
• [25]Oda N, Abe M, Sato Y: Ets-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metallo proteinases and integrin beta3. Cell Physiol 1999, 178:121-132.
• [26]Nakada M, Yamashita J, Okada Y, Sato H: Ets1 positively regulates expression of urokinase-type plasminogen activator (uPA) and invasiveness of astrocytic tumors. J Neuropathol Exp Neurol 1999, 58:329-334.
• [27]Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP, Schuetz JD: Mutant p53 cooperates with Ets and selectively up-regulates human MDR1 not MRP1. Biol Chem 2001, 276:39359-39367.
• [28]Zhou W, Muggerud AA, Vu P, Due EU, Sørlie T, Børresen-Dale AL, Wärnberg F, Langerød A: Full sequencing of TP53 identify identical mutations in situ and invasive components in breast cancer suggesting clonal evolution. Mol Oncol 2009, 3(3):214-219.
• [29]Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR: Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res 2000, 6(2):443-541.